Updated May 2026 · SEC EDGAR data
How Did Bristol-Myers Squibb (BMY) Perform?
Bristol-Myers Squibb (BMY) is currently classified NEUTRAL on the EarningsCallAI operator signal, with HIGH confidence, drawn from 8 quarters of SEC EDGAR XBRL filings and earnings call commentary. Latest reported revenue is $11.5B. Revenue grew -3.4% year-over-year. EPS came in at $1.31, with net income of $2.7B. Sector: Healthcare.
Headline Numbers
What the NEUTRAL Signal Means
Bristol-Myers Squibb is currently classified NEUTRAL with high confidence. Recent quarters are roughly flat with no decisive trend in either direction; management commentary is steady-state. This is "business as usual" with no major up or down signal for operators in the same market.
Revenue Trajectory
Bristol-Myers Squibb saw revenue decline +3.4% year-over-year. Mid-single-digit declines at this scale typically signal demand pressure or pricing erosion. Read the prepared remarks for management framing of root cause and expected duration.
Net income of $2.7B on $11.5B of revenue works out to a 23.3 percent net margin, exceptionally strong profitability. Margins this high typically reflect software-style scale economics, a dominant market position, or a particularly favorable product mix.
Quarterly Profile
| Metric | Value |
|---|---|
| Operator Signal | NEUTRAL |
| Signal Confidence | HIGH |
| Sector | Healthcare |
| Quarters Tracked | 8 |
How the Signal Is Calculated
The EarningsCallAI operator signal blends a quantitative read of revenue trajectory across the most recent four to eight quarters with a qualitative read of management commentary in the earnings call. Both inputs come from primary public sources: SEC EDGAR XBRL filings for structured financials, and SEC Form 8-K earnings releases for management commentary. Where the two inputs agree, signal confidence is HIGH; where they conflict, confidence drops. Read the full methodology for the formal classification rules.
Frequently Asked Questions
How did Bristol-Myers Squibb perform in its latest earnings report?
Bristol-Myers Squibb reported $11.5B in revenue and $1.31 EPS in the most recent quarter filed on SEC EDGAR. Year-over-year revenue growth was -3.4%. The current operator signal is NEUTRAL with HIGH confidence.
What does Bristol-Myers Squibb's NEUTRAL signal mean?
NEUTRAL means recent results are roughly flat with no decisive direction. The business is in steady state.
Where does Bristol-Myers Squibb's data come from?
All structured financials, revenue, EPS, net income, growth rates, are pulled directly from Bristol-Myers Squibb's SEC EDGAR XBRL filings (10-K, 10-Q). Operator signal classification is EarningsCallAI methodology, applied consistently across all S&P 500 companies and updated each earnings season. EDGAR data is in the public domain.
What sector is Bristol-Myers Squibb in?
Bristol-Myers Squibb is classified in the Healthcare sector. The classification follows standard S&P 500 sector taxonomy. To see how Bristol-Myers Squibb compares to other companies in the same sector, browse the sector page or use the side-by-side comparison tool.
Is the NEUTRAL signal investment advice?
No. The operator signal is built for business operators evaluating market demand and competitive trends, not for stock trading decisions. A TAILWIND signal does not mean buy the stock; a HEADWIND signal does not mean sell. Always consult a licensed financial advisor before making investment decisions.
Bristol-Myers Squibb (BMY) is currently classified NEUTRAL on the EarningsCallAI operator signal, with HIGH confidence, drawn from 8 quarters of SEC EDGAR XBRL filings and earnings call commentary. Latest reported revenue is $11.5B. Revenue grew -3.4% year-over-year. EPS came in at $1.31, with net income of $2.7B. Sector: Healthcare.